ReviewEndocrine reviews2014
Adrenocortical carcinoma.
Review in Endocrine reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06831175 (Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma), which is not on this map. Cited by 451 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
Who cites it
451 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Benign androgen-producing adrenal tumors: A systematic review of cases and case series.Endocrine · 2026Pooled it
- The differential diagnosis of adrenocortical tumors: systematic review of Ki-67 and IGF2 and meta-analysis of Ki-67.Reviews in endocrine & metabolic disorders · 2025Pooled it
- Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature.Endocrine · 2024Pooled it
- Reoperation for Recurrent Adrenocortical Carcinoma: A Systematic Review and Pooled Analysis of Population-Based Studies.Frontiers in surgery · 2022Pooled it
- Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial.Nature communications · 2024Trial
- Clinical and pathological features of oncocytic adrenocortical carcinoma: a retrospective comparative study.Journal of endocrinological investigation · 2026Article
- Concomitant parathyroid hormone-secreting oncocytic adrenocortical carcinoma and parathyroid adenoma.JCEM case reports · 2026Article
- Clinicopathologic, immunohistochemical, and molecular correlates in resected primary adrenocortical carcinoma: a single-institution cohort study.Virchows Archiv : an international journal of pathology · 2026Article
- Human biomarker navigator.iMeta · 2026Review
- Gemcitabine and oxaliplatin combination in patients with advanced adrenocortical carcinoma.Journal of the Endocrine Society · 2026Article
- Article
- Genomic Catastrophe Defines the Evolutionary Trajectory of Adrenocortical Carcinoma.Endocrine pathology · 2026Article
- Analysis of clinical and pathological characteristics of classic adrenocortical carcinoma.Scientific reports · 2026Article
- Association of Age with Outcomes in Adrenocortical Carcinoma: A Combined Cancer Registry and Multi-Omic Analysis.Cancers · 2026Article
- Pseudo-Progression Observed During Immune Checkpoint Inhibitor Therapy for Advanced Adrenocortical Carcinoma.IJU case reports · 2026Article
- Clinicopathologic Determinants of Overall Survival in Adrenocortical Carcinoma: A SEER-Based Population Study.Cancers · 2026Article
- Rare Association Between Neurofibromatosis Type 1 and Adrenocortical Carcinoma.Clinical case reports · 2026Article
- Contemporary Approaches to Adrenocortical Carcinoma.Hematology/oncology clinics of North America · 2026Review
- Impact of en bloc extended R0 resections on oncological outcome of locally advanced adrenocortical carcinoma.Updates in surgery · 2026Article
- Machine Learning Approach for Differentiation of Pheochromocytoma from Adrenocortical Cancer and Non-Functioning Adrenal Adenomas.Life (Basel, Switzerland) · 2026Article
391 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy, often with an unfavorable prognosis. Here we summarize the knowledge about diagnosis, epidemiology, pathophysiology, and therapy of ACC. Over recent years, multidisciplinary clinics have formed and the first international treatment trials have been conducted. This review focuses on evidence gained from recent basic science and clinical research and provides perspectives from the experience of a large multidisciplinary clinic dedicated to the care of patients with ACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.